Skip to main content
AmigoFish

The Fellow on Call: The Heme/Onc Podcast

Rouleaux University Medical CenterAudio

Format:
Podcast
New episodes:
Weekly
Latest episode:
Not rated yet
CosmosOpen at the sourceReport a problemIs this your show? Get a badge

About this show

We quickly realized we knew very little about hematology and oncology when we started fellowship. Our goal is to bring you the fundamentals, core concepts and important management approaches in our field, driven by the latest evidence and expert opinion. In each episode, we will provide bite-sized, simplified approaches to common questions in a way that is perfect for anyone interested in hematology and oncology, from students and trainees to advanced practice providers and practicing physicians.

Covers: medicine, oncology, hematology, pancreatic cancer, head and neck cancer, chronic lymphocytic leukemia, clinical trials, medical education

Show details and episodes come from the publisher's public feed at thefellowoncall.com. Last updated . Names, artwork and text belong to their publishers.

Recently on this show

Summary of recent episodes, drawn from the publisher's feed.

The Fellow on Call explains core hematology and oncology concepts in bite-sized, simplified form. Recent episodes cover pancreatic cancer from diagnosis to metastatic disease, CLL frontline and relapsed updates, and head and neck cancer.

Report a problem with this summary

Cosmos

Similar in subject

See the full Cosmos

Similar shows

See all Education shows

Explore more

Episodes

  • Episode 170: Career Development Series- How to Navigate the ASH Annual Meeting

    This week, we are so excited to share the fourth episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH Trainee Council, and Hematopoiesis! For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this happen! This week, we interview Nick Lee, MD, Chair of the ASH Trainee Council, as he shares his insights on how trainees attending their first ASH Meeting can best prepare and how to make the most of their time at the meeting! ** This episode is created in partnership with The American Society of Hematology (https://www.hematology.org/), The ASH Trainee Council (https://www.hematology.org/education/trainees/fellows/trainee-council), and Hematopoiesis (https://www.hematology.org/education/trainees/fellows/hematopoiesis) ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 169: Pancreatic Cancer Series, Pt. 4 – Metastatic Disease

    This week, we continue our Pancreatic Cancer series with the setting where most of our patients live: metastatic disease. Using our case of a patient with newly diagnosed metastatic pancreatic cancer, we trace how first-line chemotherapy evolved from single-agent gemcitabine to FOLFIRINOX, gemcitabine/nab-paclitaxel, and NALIRIFOX, then work through how to pick a regimen for the patient in front of you, why germline and somatic testing belong at the first visit, what the POLO trial does and doesn't tell us about maintenance olaparib, and the story of the year: daraxonrasib, the RAS(ON) inhibitor that finally drugged the "undruggable" target in RASolute 302. We finish with second-line sequencing. As always, if you haven't heard the earlier episodes in this series, including our introduction, approach to resectable disease, and approach to borderline and locally advanced disease, be sure to check those out first. And listeners - stay tuned! We will follow up these conversations with our interviews with our surgery and radiation colleagues in upcoming episodes! This episode is sponsored by Primum! As questions of oncology experts (including pancreatic cancer) free! To learn more and to sign up for your free account, visit Primum.co/fellows ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 168: Pancreatic Cancer Series, Pt. 3 – Borderline Resectable and Locally Advanced Disease

    This week we continue our Pancreatic Cancer series with the two middle categories of non-metastatic disease: borderline resectable and locally advanced. Using the case of a 61-year-old woman with a pancreatic body mass abutting the superior mesenteric artery, we walk through the vascular definitions that separate resectable, borderline resectable, and locally advanced disease, then trace how multi-agent chemotherapy borrowed from the metastatic setting became the neoadjuvant backbone. We dig into the newest challenger to mFOLFIRINOX, PAXG in the CASSANDRA trial, and the still-contested role of radiation, from Alliance A021501 to PREOPANC-2. Along the way, we cover why restaging CT can understate response, how LAP07 reframed consolidative chemoradiation in locally advanced disease, and what to offer patients who are not candidates for intensive therapy. As always, if you haven't heard the earlier episodes in this series, start there first. As always, if you haven't listened to parts 1 and 2 (episodes 165 and 166, respectively) This episode is sponsored by Primum! As questions of oncology experts (including pancreatic cancer) free! To learn more and to sign up for your free account, visit Primum.co/fellows ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 167: Pancreatic Cancer Series, Pt. 2 – Resectable Disease

    This week our pancreatic cancer series moves from diagnosis to management, starting with resectable disease. Using the case of a 68-year-old man with a 2.8 cm adenocarcinoma of the pancreatic head, we define what "resectable" actually means, review the operation and the goal of an R0 resection, and explain why surgery alone is never enough. We then trace the adjuvant story from ESPAC-1 and CONKO-001 to today's two standards, modified FOLFIRINOX (PRODIGE 24) and gemcitabine-capecitabine (ESPAC-4), before taking on the surgery-first versus neoadjuvant debate (NORPACT-1, PREOPANC, SWOG S1505), the question of preoperative biliary stenting, and what is coming next. As always, if you haven't listened to part 1 of this series, start there first. This episode is sponsored by Primum! As questions of oncology experts (including pancreatic cancer) free! To learn more and to sign up for your free account, visit Primum.co/fellows ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 166: Pancreatic Cancer Series, Pt. 1 – Biology, Diagnosis, and Staging

    This week we kick off a brand-new series on pancreatic cancer, starting with the fundamentals. Using the case of a 68-year-old man with painless jaundice, weight loss, and new-onset diabetes, we cover the epidemiology and sobering survival statistics of pancreatic ductal adenocarcinoma, the major risk factors (and why late-onset diabetes is often a consequence rather than a cause), universal germline testing and the hereditary syndromes worth knowing for the boards, and how tumor location in the head, body, or tail shapes presentation. We then walk through the diagnostic workup (pancreatic-protocol CT, MRI/MRCP, EUS-guided biopsy, and the therapeutic role of ERCP), the pitfalls of CA 19-9, precursor lesions and the four-gene molecular story led by KRAS, somatic profiling for actionable targets, and the resectability framework that will drive treatment decisions for the rest of the series. This episode is sponsored by Primum! As questions of oncology experts (including pancreatic cancer) free! To learn more and to sign up for your free account, visit Primum.co/fellows ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 165: CLL Updates Series, Pt. 2 – Relapsed/Refractory in 2026

    This week we wrap up our two-part CLL update by turning to relapsed and refractory disease. We pick up with the 68-year-old man from Part 1, now a year out from frontline therapy and showing signs of relapse. We cover when relapse actually needs treatment, the history of BTK inhibitor resistance and why BTK mutation testing matters, and how to sequence therapy now that BTK inhibitors and venetoclax have both moved into the frontline. From there we get into venetoclax retreatment, the pirtobrutinib data from BRUIN CLL-321 and the new BRUIN CLL-322 triplet trial, the real-world CAR T experience that is changing how we think about cell therapy in CLL, bispecific antibodies, and the emerging class of BTK degraders. As always, if you haven't heard the earlier episodes in this series, start there first. If you haven’t done so, be sure to check out our original CLL Series and our CLL Updates Part I episode as this update will draw on concepts covered previously! **This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, click here! Be sure to use our SPECIAL TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 164: CLL Updates Series, Pt. 1 – Frontline Therapy in 2026

    This week we kick off a two-part update to our CLL series, covering what has changed in frontline management since our original episodes. Using the case of a 68-year-old man with newly diagnosed, symptomatic CLL, we revisit the essential steps before treatment: confirming an indication to treat, ruling out Richter's transformation, and risk stratification, with the history behind FISH cytogenetics, IGHV status, and the CLL-IPI. We then trace how continuous BTK inhibitors and fixed-duration venetoclax-obinutuzumab displaced chemoimmunotherapy, before digging into the trials reshaping practice in 2026: AMPLIFY, SEQUOIA Arm D, and CLL17. Along the way, we cover the open questions for TP53-aberrant disease and why MRD, although prognostic, is not yet a reliable guide for treatment decisions with novel agents. If you haven’t done so, be sure to check out our original CLL Series, as these updates will draw on concepts covered previously! **This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, click here! Be sure to use our SPECIAL TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 163: Head and Neck Cancer Series, Pt. 5 – Recurrent, Relapsed, and Metastatic Disease

    This week the Head and Neck series turns to what happens when local therapy isn't enough — recurrent, relapsed, and metastatic disease. Using the case of a woman with a laryngeal cancer recurrence, we work through the first and most important question (recurrence versus second primary), the workup and biomarkers that steer therapy, local salvage options, the CPS-driven first-line systemic algorithm, second-line and beyond, the distinct world of nasopharyngeal cancer, oligometastatic disease, and the central role of early palliative and supportive care. As always, if you haven't heard the earlier episodes in this series, start there first. **This episode is sponsored by Primum! Sign up for your free account at primum.co/fellows (http://primum.co/fellows) ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 162: Head and Neck Cancer Series, Pt. 4 – Discussion with Radiation Oncology

    This week the Head and Neck series turns to radiation oncology, with guest Dr. David Palma, a Professor and Radiation Oncologist at the Verspeeten Family Cancer Centre and professor at the Schulich School of Medicine and Dentistry, Western University (London, Ontario). A clinician-scientist who splits his time between clinical-trials research and treating head and neck and lung cancers, David walks us through how radiation actually works and gets planned, the de-escalation question, PET after treatment, larynx preservation, re-irradiation, oligometastatic disease, and the proton-versus-photon debate - all with some of the best analogies we've had on the show. **This episode is sponsored by Primum! Sign up for your free account at primum.co/fellows (http://primum.co/fellows) ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 161: Career Development Series- Building a Career in Clinical Research

    This week, we are so excited to share the third episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH Trainee Council, and Hematopoiesis! For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this happen! This week, we interview Hanny Al-Samkari, MD as he shares his insights on what constitutes clinical research, what a career in clinical research might look like, and how trainees can get involved in clinical research. ** This episode is created in partnership with The American Society of Hematology (https://www.hematology.org/), The ASH Trainee Council (https://www.hematology.org/education/trainees/fellows/trainee-council), and Hematopoiesis (https://www.hematology.org/education/trainees/fellows/hematopoiesis) ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 160: Head and Neck Cancer Series, Pt. 3 – Discussion with ENT

    Throughout this series, we have discussed how multidisciplinary the management of head and neck cancer is and the critical role that our surgical colleagues play in the management of this disease. This week, we welcome Dr. Michael Topf, Associate Professor for Associate Professor of Otolaryngology-Head and Neck Surgery at Vanderbilt University Medical Center to our show to share with us how he determines which patients are appropriate for surgery, what his approach is, and so much more. It’s rare that we get insights into the factors that our surgery colleagues think about when determining surgical candidacy and surgical approaches and so get ready for an incredibly informative conversation! Another high yield episode you do not to miss! **This episode is sponsored by Primum! Sign up for your free account at primum.co/fellows (http://primum.co/fellows) ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 159: Head and Neck Cancer Series, Pt. 2 – Locoregional Disease

    This week we get into treatment. Building on Part 1's (episode 158: https://www.thefellowoncall.com/tfocpodcast/hncintro) workup and staging, we walk through three cases to highlight the important distinguishing details: an oral cavity cancer, a locally advanced oropharynx cancer, and a larynx cancer. Content: - Approach to locoregional oral, oropharynx, and larynx cancers - How we arrived at the current dosing paradigms for chemotherapy for chemoRT - Is there a role for induction therapy? - What are the data for immunotherapy in this space? - High risk factors and why they matter **This episode is sponsored by Primum! Sign up for your free account at primum.co/fellows (http://primum.co/fellows) ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 158: Head and Neck Cancer Series, Pt. 1 - Introduction

    This week, we kick off our Head and Neck Cancer series. Using the case of a man with a painless neck mass, we build a framework for the whole series. Content: - Why head and neck cancer is really two distinct diseases - The biology behind HPV-associated oropharyngeal cancer - How to work up a neck mass and hunt for an unknown primary - The cervical lymph node levels, and AJCC 8th edition staging - How "Stage IV" does not mean metastatic in HPV-positive disease **This episode is sponsored by Primum! Sign up for your free account at primum.co/fellows (http://primum.co/fellows) ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 157: Immune Thrombocytopenic Purpura Series, Pt 3- Challenging Scenarios in ITP

    This week, we put everything we talked about in our ITP series together and talk about how we manage ITP in complicated patient scenarios. Through a case-based discussion, we discuss how to we would approach each of these complicated scenarios. If you haven’t done so already, be sure to check out episodes 155 and 156! Content: - ITP management in pregnancy - ITP management in a patient with new VTE - ITP management in a patient with acute bleeding - Refractory thrombocytopenia management despite multiple lines of therapy - ITP management in a patient with TPO-RA side effect intolerance ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 156: Immune Thrombocytopenic Purpura Series, Pt 2- Relapsed/Refractory

    This week, we move to the relapsed/refractory ITP setting, focusing on what options are available to patients after their initial treatment with steroids ± IVIg, which we discussed in Episode 155. If you have not done so already, definitely listen to that episode as we build on the topics discussed here today! Content: - What are options after steroids? - How to counsel patients on options? - Is there a correct way to sequence available options? ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 155: Immune Thrombocytopenic Purpura Series, Pt 1- First Line Management

    This week, we go back to Classical Hematology! We previously discussed the initial workup and management of ITP in Episode 009, but now it’s time to dig deeper. What do we do once we make the diagnosis? How do we approach management when we have a new diagnosis? Content: - Refresher on diagnosis of ITP - Response criteria - What warrants a hospital admission vs. outpatient management? - What is our approach to initial inpatient management? - When is it safe to discharge a patient from the hospital? ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 154: Ask The Program Directors-The Do’s and Don'ts of Applying to Hematology Fellowship (Career Development Series)

    This week, we are so excited to share the second episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH Trainee Council, and Hematopoiesis! For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this happen! With fellowship application season around the corner, we thought that this was the perfect time to understand what program directors are looking for in their applicants. This time, we welcome Dr. Alice Ma, Hematology/Oncology Fellowship Director at UNC, and Dr. Gerald Hsu, Hematology/Oncology Fellowship Director at UCSF. Along with our guest hosts, Nick and Claire, we ask the tough questions that all of wish we could ask but never could. This is an episode you do not want to miss! ** This episode is created in partnership with The American Society of Hematology (https://www.hematology.org/), The ASH Trainee Council (https://www.hematology.org/education/trainees/fellows/trainee-council), and Hematopoiesis (https://www.hematology.org/education/trainees/fellows/hematopoiesis) ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 153: Myeloma Capstone, Pt 2 - MRD-Guided Therapy, Maintenance, and Relapsed/Refractory Sequencing

    Therapy, Maintenance, and Relapsed/Refractory Sequencing This week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the Huntsman Cancer Institute at the University of Utah, and introduce a new friend of the show, Dr. Adeel Khan from UT Southwestern. In part two, we cover three practical and rapidly evolving topics: the role of MRD testing in guiding treatment decisions, how to individualize maintenance therapy in 2026, and how to approach sequencing of CAR-T and bispecific therapies in the relapsed/refractory setting. In this week’s show notes, we summarize the key thoughts about how our experts think about approach to their patients. If you have not already done so, be sure to check out Part 1 of this discussion! Content: - What are the practical implications of MRD-testing in myeloma treatment? - How do we think about maintenance therapy in the present day? - What therapies are on the horizon? - How do we approach management of younger patients with relapsed/refractory disease? - How do we approach bridging therapy? ** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows (http://primum.co/fellows). As a special bonus, one of our guests, Dr. Mohyuddin, is an expert on Primum ready for your questions! ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 152: Myeloma Capstone, Pt 1 - Smoldering Myeloma & Frontline Treatment in the Elderly

    This week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the Huntsman Cancer Institute at the University of Utah, and introduce a new friend of the show, Dr. Adeel Khan from UT Southwestern. In part one, we tackle two highly practical topics: the AQUILA trial and its real-world implications for smoldering myeloma management, and how to approach frontline therapy in the older myeloma patient. In this week’s show notes, we summarize the key thoughts about how our experts think about approach to their patients. Stay tuned for part 2 of this discussion next week! Content: - How do our experts approach the management of smoldering multiple myeloma in light of the AQUILA study - What is our experts' approach to older patients with newly diagnosed multiple myeloma ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet
  • Episode 151: Myeloma Series, Pt. 11 - Role of bispecific T-cell engagers for relapsed/refractory multiple myeloma (2026)

    In this week’s episode, we continue our journey through the relapsed/refractory myeloma space, with a focus on the role of bispecific T-cell engagers. Another incredibly important conversation that is so important in the current treatment landscape and one that you don’t want to miss. If you haven’t done so already, be sure to check out our CAR T episode. Content: - What are bispecific T-cell engagers? - How are they different than CAR T? - A discussion of the pivotal MajesTEC-3 trial (NEJM 2025) - What are key side effects? - How to sequence CAR T vs. bispecific T-cell engagers? ** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast (http://llmcongress.com/podcast)! Be sure to use our special TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube

    Not rated yet